Podcasts about World Diabetes Day

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

Here's your latest ECR Newswatch bulletin from the team at East Coast Radio. Website

Bongani Bingwa speaks to Dr Sindeep Bhana, a senior endocrinologist and specialist physician, about World Diabetes Day, we’re shining a light on a disease that creeps into homes and lives with almost no warning. In South Africa, millions are living with it, and government officials now rank it among the country’s top killers. The rise of type 2 diabetes tells its own story: more processed food, more sugary drinks, bigger portions, less movement, and an alarming rise in obesity. 702 Breakfast with Bongani Bingwa is broadcast on 702, a Johannesburg based talk radio station. Bongani makes sense of the news, interviews the key newsmakers of the day, and holds those in power to account on your behalf. The team bring you all you need to know to start your day Thank you for listening to a podcast from 702 Breakfast with Bongani Bingwa Listen live on Primedia+ weekdays from 06:00 and 09:00 (SA Time) to Breakfast with Bongani Bingwa broadcast on 702: https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/36edSLV or find all the catch-up podcasts here https://buff.ly/zEcM35T Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702See omnystudio.com/listener for privacy information.

Can Nigeria curb its diabetes crisis with tech, awareness, and policy reforms on World Diabetes Day?

Elton Davids, All My Sports SA spoke to Clarence Ford about the Local Type 1 Diabetes Awareness Walk taking place on Seapoint Promenade on World Diabetes Day. Views and News with Clarence Ford is the mid-morning show on CapeTalk. This 3-hour long programme shares and reflects a broad array of perspectives. It is inspirational, passionate and positive. Host Clarence Ford’s gentle curiosity and dapper demeanour leave listeners feeling motivated and empowered. Known for his love of jazz and golf, Clarrie covers a range of themes including relationships, heritage and philosophy. Popular segments include Barbs’ Wire at 9:30am (Mon-Thurs) and The Naked Scientist at 9:30 on Fridays. Thank you for listening to a podcast from Views & News with Clarence Ford Listen live on Primedia+ weekdays between 09:00 and 12:00 (SA Time) to Views and News with Clarence Ford broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/erjiQj2 or find all the catch-up podcasts here https://buff.ly/BdpaXRn Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

The Gauteng Health department is gearing up to mark World Diabetes Day today in Soweto. The event, being held in partnership with Novo Nordisk and the City of Johannesburg, aims to raise awareness about diabetes and the challenges people with the condition face, especially in the workplace. This year's campaign focuses on promoting healthier lifestyles and encouraging early screening to reduce the risk of complications like heart disease and kidney damage. Elvis Presslin spoke to Patrick Magodzho, Deputy Director of Non-Communicable Diseases at the Gauteng Department of Health

In this episode, we bring you more reaction from the farming community after news this week that a local veterinary practice will soon withdraw its farm services.As the world marks World Diabetes Day, we talk to parents about the everyday reality of raising a child with diabetes the challenges, the routines, and the support they rely on.We also look into something you might not have thought about: how much it actually costs the Department of Infrastructure to produce car tax discs each month.

Diabetes affects hundreds of millions worldwide, but how much do we truly understand about it? Join us for a light, informative quiz that breaks down the facts, busts a few myths, and helps raise awareness on this important global health day. Presented by Audrey Siek, Ryan Huang and Emaad Akhtar Produced by Audrey Siek Edited by Trisha Yeong Photo and music credit: Pixabay & its talented community of contributorsSee omnystudio.com/listener for privacy information.

Oh hey, it's World Diabetes Day 2025. I thought I'd take the opportunity to do a little solo episode based on some questions you sent in, in the spirit of having a little chat about the very real and often ridiculous stuff we go through regularly as people with type 1 diabetes, but that we don't often get to speak about.I talk a bit about type 1 diabetes and the workplace, then there's some travel chat, and then we get to the good stuff thanks to a question about type 1 diabetes embarrassment. Where do we begin...DISCLAIMER Nothing you hear on Type 1 on 1 should be taken as medical advice. Please consult your healthcare team before making any changes to your diabetes or health management.EPISODES MENTIONED:Travelling with type 1 and the latest in diabetes tech with Diabetech's Justin EastzerType 1 Diabetes Travel Essentials with Diabetech's Justin Eastzer46 years with type 1 diabetes - episode with Maryann Croft MaloneyAn Introduction to Hybrid Closed Loop: The Technical (Part 1/2)An Introduction to Hybrid Closed Loop: The Emotional (Part 2/2)JOIN THE TYPE 1 ON 1 COMMUNITY:Come and say hi @studiotype1on1 on Instagram.Visit the Type 1 on 1 website.Subscribe to the Type 1 on 1 newsletter.SPONSOR MESSAGEThis episode of Type 1 on 1 is sponsored by Dexcom. Using Dexcom CGM has given me so much confidence to make informed diabetes treatment decisions in the moment.You can choose to wear it on your arm or your abdomen, and all Dexcom CGMs have the share and follow feature even when connected to an insulin pump, so family and friends can see your glucose levels and get alerts, giving that extra bit of support when needed.Head to Dexcom.com to request a free Dexcom ONE+ sample.Always read the user manual for important product aspects and limitations. Talk to your doctor for diabetes management terms and conditions and terms of use. 

The DPC met to discuss plans for St Andrew's Church and more — Katy Docker brought us the latest.The Gibraltar Red Cross launches a Jamaica Appeal after Hurricane Melissa — Chair Tim Bristow told us more. Ahead of World Diabetes Day, we heard about the Walk for Diabetes and Circle of Light Ceremony with Courtney and Melanie. A fusion of art and food with Callarte — Joseph Alecio from the Fine Arts Associtaion and artist Aaron Soleci shared how creativity is hitting the table.And Rock the Rock returns to The Ivy for the GBC Open Day — we'll chat to Chris Osborne and GAMPA's rock band Kaos Theory. Hosted on Acast. See acast.com/privacy for more information.

Juggling training, nutrition, and day-to-day life can be a challenge. But throw in the complexities of Type 1 Diabetes, and it's a whole new ball game. In this special episode to coincide with World Diabetes Day, I'm joined by co-founder of Enhance-d and former head of research at Team Novo Nordisk, Sam Scott. Sam gives us a peek into the world of diabetes management for the endurance athlete. We'll discuss what Type 1 diabetes actually is, how it's managed, the impact of exercise, and the innovations in devices and data management that are making life a little easier to make this all work. Whether you're an athlete with Type 1, a nutrition practitioner, or you're just curious what it's all about, there'll be plenty in this episode for you.   Timestamps: 03:13 - Sam's background and how he came to work in diabetes and exercise 13:07 - What is Type 1 Diabetes and how is it managed? 25:57 - How does exercise affect blood glucose control with Type 1 Diabetes? 35:26 - Giving insulin with a pen vs a pump for athletes 41:38 - 'Closed loop' systems for glucose monitoring and insulin delivery in athletes 45:41 - Does high volume endurance training make diabetes management harder? 50:11 - Sam's role at Team Novo Nordisk (professional cycling team where all riders have Type 1 Diabetes) 56:59 - Tech and data insights, including Sam's role in founding Enhance-d, and the role of AI in diabetes management 1:08:28 - Very low carb diets and the very high carb (during exercise) trend in athletes with Type 1 Diabetes 1:11:33 - The future of nutrition, exercise and Type 1 Diabetes 1:14:13 - Summary and wrap up   Sam's work: LinkedIn: linkedin.com/in/sam-scott-phd-620a97a2/  Sam's book: Empowered: The Science of Exercise with Type 1 Diabetes (available from Amazon) Enhance-d (bringing together data on exercise and diabetes management): enhance-d.com    Fueling Endurance eBook | T -12 Race Nutrition Course | Practitioner Resources The Fueling Endurance eBook contains answers to 49 of the most common nutrition questions that runners, cyclists and triathletes ask, and contains insights, tips, and quotes from experts and athletes.  The T -12 self-guided course will help prepare you for your next event, with online tools, guides, information and instructions to take you through the 12 weeks leading up to race day. And the Fueling Endurance Practitioner Membership provides access to online tools and calculators I use all the time when working with endurance and ultraendurance athletes. This includes working out the carbohydrate needs for runners (road and trail) and cyclists for different types of training sessions. For more into on each of these, check out fuelingendurance.com.  

In this episode, I sit down with Patrick House, who's lived with type 1 diabetes for 35 years and came to coaching feeling completely burnt out. He opens up about rebuilding trust with his body, shifting from self-blame to self-compassion, and how a late ADHD diagnosis changed everything. Let's be honest… we don't hear enough male voices talking about type 1 diabetes, burnout, or what it actually looks like to heal from the inside out, and Patrick's story proves something I want everyone listening to hear. If you're looking for a sign to ask for help, here it is:

Getting your diabetes supplies shouldn't be so complicated and we're here to help spread the word. Today, we're joined by Stephen Ouellette from Byram Healthcare to unpack what's happening behind the scenes that makes this part of life with T1D so frustrating. From prescription renewal timelines and insurance authorizations to communication gaps, we break down the biggest challenges and what you can do to stay ahead of them. If you live with T1D, you know how stressful it can be when supplies don't arrive on time—so even if this isn't your biggest diabetes stressor right now, consider sharing this episode to support those who are feeling that weight. Anyone in the T1D community will walk away from this conversation not only more informed, but also empowered and validated.Quick Takeaways: The surprising story behind Byram Health & how Stephen found his way into diabetes care How patient support has evolved and what that means for people living with T1D todayA behind-the-scenes look at how your diabetes supplies are ordered, approved, and shippedWhy supply delays happen (and what you can do to prevent them)The simple steps to start home delivery through Byram Health and make ordering your medical supplies stress-freeWhat to do now: 

Meet Coach Alejandro, the newest member of our Risely Health coaching team! His journey with type 1 diabetes is deeply personal, from being the first in his family diagnosed to later supporting his young daughter through her own diagnosis. Instead of letting diabetes define their story, Alejandro turned it into his purpose, becoming a health coach and diabetes educator to help others find more freedom and confidence in their own journeys. We also share a special announcement: Risely is now offering coaching in Spanish, and Alejandro is leading the way in expanding our mission to support even more people living with T1D around the world. Please share this episode to help us spread the word! Quick Takeaways:Alejandro's Personal Journey with T1D: “Diabetes became like a shared language in our family across three generations.”Life-Changing Experience Before Receiving His T1D diagnosis Finding Purpose Through His Diagnosis: “I realized why I had been diagnosed…”From Lived Experience to Coaching Others: “With the right mindset and support, life with diabetes can be not just manageable, but deeply meaningful.”Advice for Handling Tough Blood Sugar Days (as a T1D & T1D parent) What to do now:

Adapting to a type 1 diabetes diagnosis is no small thing, and many of you will resonate with the discomfort Gavin Griffiths experienced as he tried to move through life as a teenager in the early 2000s alongside the diagnosis he received at the age of 8. In this episode Gavin details how after some tough years, a conversation with a younger, newly-diagnosed classmate flipped a switch that would send Gavin on a path of global diabetes leadership. Forming the charity Diathlete soon after it's still going strong, hosting the renowned League of Diabetes support and education network.This World Diabetes Day on November 14th it will host a T1D festival and fashion show in London, and you're invited!Throughout the years Gavin has led with heart in order to push for change, connection and visiblity for people living with type 1 diabetes across the world. It even helped him to find love with his wife Paula, who also lives with type 1 diabetes.Dedicated to their mission while juggling full-time careers, the pair's combined passion and power has rippled, one conversation at a time, to help people's understanding and experience of living with type 1 diabetes for the better.The Chronicles of Glycaemia is Gavin's first book, also due to be released on World Diabetes Day 2025. Find out more about the T1D Festival.Get tickets to the T1D Festival on Friday 14th November.League of Diabetes website.League of Diabetes Instagram.Gavin Griffiths Instagram.Gavin Griffiths Facebook.DISCLAIMER Nothing you hear on Type 1 on 1 should be taken as medical advice. Please consult your healthcare team before making any changes to your diabetes or health management.JOIN THE TYPE 1 ON 1 COMMUNITY:Come and say hi @studiotype1on1 on Instagram.Visit the Type 1 on 1 website.Subscribe to the Type 1 on 1 newsletter.SPONSOR MESSAGE This episode of Type 1 on 1 is sponsored by Dexcom. Using Dexcom CGM has given me so much confidence to make informed diabetes treatment decisions in the moment.You can choose to wear it on your arm or your abdomen, and all Dexcom CGMs have the share and follow feature even when connected to an insulin pump, so family and friends can see your glucose levels and get alerts, giving that extra bit of support when needed.Head to Dexcom.com to request a free Dexcom ONE+ sample.Always read the user manual for important product aspects and limitations. Talk to your doctor for diabetes management terms and conditions and terms of use. 

In this solo episode, I'm spilling all the behind-the-scenes details from filming Beyond Type One's Go Beyond campaign with Nick Jonas, Billy Porter, and more. From navigating pregnancy on set to what this experience taught me about breaking stigma and owning your story, it's one you don't want to miss. Plus, I'm dropping a sneak peek at our Rising Above World Diabetes Day event featuring Dancing with the Stars' Rylee Arnold!Quick Takeaways:Inside scoop from the Go Beyond Campaign by Beyond Type 1 Behind the scenes of filming a T1D shoot “At one point, Mr. Nick Jonas walks in…”How impactful misconceptions are (especially to the T1D community) Big announcement about our upcoming event for World Diabetes Day 

[SPONSORISÉ] Diabetes is a chronic disease that affects 800 million people worldwide. What is their daily life like? What are the solutions contributing to improving their quality of life? How are healthcare providers mobilizing to deliver the relevant answers? Beyond preconceived ideas, let's discover the advances that contribute to make the life of patients easier: connected solutions, personalized support... In this episode, Agnieszka Kula-Borsuk, VP Home Healthcare in Europe at Air Liquide, explains how personalized support for people living with diabetes contributes to improving their daily quality of life. A podcast to listen to, whether you are concerned or simply curious! _ Thanks to Group experts and passionate employees, we reveal to you behind the scenes of innovation, to better understand the importance of these advances and their impact on our lives. Join us today to help shape the world of tomorrow : https://www.airliquide.com/join-us/careers-air-liquide Air Liquide is a world leader in gases, technologies and services for industry and health. Oxygen, nitrogen and hydrogen are small molecules essential to life, matter and energy. They embody Air Liquide's scientific territory and have been at the heart of the Group's business since its creation in 1902. _ Pour écouter la version française, c'est plus bas

This episode is in honor of Kylee Breann Whitley, a daughter, a sister, an aunt, and a friend living with type 1 diabetes. In this deeply emotional conversation, Dr. Joren Whitley opens up about the life and loss of his sister, Kylee-a bright, adventurous young woman who lived with type 1 diabetes and battled diabulimia, an often-misunderstood eating disorder. This is not just about loss, it is a call to action for families, friends, and healthcare providers, and what we can all learn from one family's journey. While this episode touches on heavy topics, it's ultimately one of love, remembrance, and hope. If you know someone living with type 1 diabetes, what you hear today could truly save a life. Please share it and help save lives. Quick Takeaways:The annual mortality rate for diabulimia is estimated to be 34.8% (yet it wasn't recognized in literature until after 2007).“I help hundreds of people every single week, and I couldn't help the one person who was closest to me.” – Dr. Joren WhitleyA type 1 diabetes diagnosis through a sibling's eyes: “I just remember her struggling.”The hidden danger of diabulimia: how insulin omission and lack of awareness can turn deadly.The call to action: what Kylee's story teaches us about advocacy, early intervention, and the power of speaking up.

Today's guest is a dear friend of mine who I've shared many meals with, a few stages before, Kyle Banks. In the middle of living out his dreams, performing on Broadway and working with some of the biggest names in the music industry, a type 1 diabetes diagnosis changed everything. In this episode, Kyle shares his journey from the bright lights of Broadway to starting up Kyler Cares and how that work has grown from helping a few families in his network with diabetes to serving over 2000 students with T1D in the New York City public school system. We'll talk about the problems these kids and families are facing, how Kyle secured a major grant to tackle them, and why this work has the potential to scale nationwide. This conversation is going to be inspiring, eye-opening, and one that you're going to want to hear all the way through. Quick Takeaways:Kyle's story Addressing the needs of T1D families and getting them the support they need The biggest problem kids with Type 1 Diabetes are facing in public schools right now Project 31 ‼️ Our annual event Rising Above T1D is BACK!

If you've been afraid of carbs or you were told that eating fewer carbs is the only way to manage blood sugars, today's episode is for you. We're breaking down everything that people with T1D need to know to make empowered choices with food and have a healthy relationship with it. To help us understand why we need carbs and officially debunk these myths, is Bridget Wood– Registered and Licensed Dietitian, Certified Diabetes Care and Education Specialist, highly respected expert in diabetes and nutrition, with over 15 years of personal experience living with T1D. This is what a conversation about T1D and food should actually sound like. Be sure to share it to help this message reach more people in our community. How your relationship with food shapes your diabetes management Debunking the myth that all carbohydrates cause high blood sugarOvercoming fear of insulin and fostering a positive relationship with itThe lasting impact of restrictive dieting: “When we remove things from our diet, our relationships with food can be tainted forever.' 5 tips for able being able to eat carbs and stay in range more effectively

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Pre-diabetes marks the initial phase of diabetes. A fasting blood sugar level below 110 mg/dL is considered normal. If it ranges from 110 to 126 mg/dL, you are classified as pre-diabetic. The Oral Glucose Tolerance Test (OGTT) involves consuming 75 grams of glucose, followed by a blood sugar test two hours later. A result below 140 mg/dL is normal, while a range of 140 to 199 mg/dL indicates pre-diabetes. Additionally, HbA1c levels provide long-term insights into blood sugar control. Levels below 5.7% is normal, 5.7% to 6.4% indicate pre-diabetes, and 6.5% or higher signify diabetes. All people with diabetes cases progress through the pre-diabetes stage. World Diabetes Day and Awareness World Diabetes Day is celebrated on November 14th, coinciding with the birthday of Frederick Banting, the discoverer of insulin. This global initiative, led by the International Diabetes Federation, promotes awareness with an annual theme. The 2024–2026 theme focuses on Diabetes and Well-Being, and the 2024 sub-theme emphasizes Breaking Barriers, Bridging Gaps, highlighting the importance of a fulfilling life alongside managing diabetes. Gestational Diabetes and Pregnancy Hormones During pregnancy, placental hormones like human placental lactogen, (HPL), progesterone and estrogen increase insulin resistance by over 50%, impairing insulin's effectiveness. Typically, if someone's pancreas is producing about 50 units of insulin daily, during pregnancy, it may need 75–80 units per 24hr. If beta cells cannot meet this increased demand of pregnancy, blood sugar levels rises, leading to gestational diabetes. A glucose challenge test with 75 grams of glucose, followed by a blood sugar measurement after two hours, acts as a stress test for beta cell function. Levels below 140 mg/dL are normal, while levels above 140 indicate gestational diabetes. Early detection and management are crucial to ensure a healthy baby's birth. Recorded on: 8.11.2024 Recorded at: Akashwani Nagpur

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Of course, World Diabetes Day was yesterday. November 14 marks the birthday of Sir Frederick Banting. who discovered insulin along with Charles Best in 1922. Lots of the tech companies are taking action.. I'm going to link up a great article highlighting what many of them are doing…. from Medtronics Blue Balloon challenge to Dexcom's Nick Jonas video and a lot more. https://www.drugdeliverybusiness.com/world-diabetes-day-2024/ XX A new triple combo therapy could restore insulin production in people with type 1 using existing medications. Levicure's triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. The therapy is a combination of: DPP4-inhibitors, a common type 2 diabetes medication Proton pump inhibitors (PPIs), a drug for severe acid reflux A proprietary version of gamma-aminobutyric acid (GABA), a supplement often used to treat anxiety Levicure says the combined effect can block beta cell destruction, suppress autoimmunity, and restore beta cell function. So far, Levicure's triple therapy has gone through only one retrospective chart review; it has not been put to the test in a randomized controlled trial https://www.diabetesdaily.com/blog/can-this-triple-combo-oral-therapy-restore-insulin-production-733261/   XX Blue Circle Health is expanding it's unique approach to type 1 care. Already active in Florida, Maine & Vermont, it will now be in Delaware and Ohio. Blue Circle Health is free and develops a personalized care plan for each participant, tailored to their unique needs, and offers comprehensive multidisciplinary support over a six-month period. It's paid for by the Helmsley Charitable Trust. The program is available to people 18 years of age and older that speak Spanish or English, regardless of insurance coverage or citizen status. We've got an upcoming podcast episode all about Blue Circle coming up soon. https://www.prnewswire.com/news-releases/blue-circle-health-expands-to-delaware-and-ohio-to-address-health-system-barriers-to-type-1-diabetes-care-and-education-302304170.html XX An international team of experts has created the world's first evidence-based guide for eating lower and low carb. The group says until now, people with type 1 diabetes and their healthcare providers have lacked comprehensive resources to help implement this approach safely and effectively. The guide provides essential information for dietitians and nutritionists and empowers them to work collaboratively with individuals and families who are interested in reducing carbohydrates. It's free and we've got the download link in the show notes. https://www.newswire.ca/news-releases/international-team-launches-first-guide-for-carbohydrate-reduction-in-type-1-diabetes-883729104.html XX A new pump system is available in Canada. mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid closed-loop, a mobile phone-based algorithm, and the Dexcom G6 Continuous Glucose Monitoring (CGM) System. Working together, these components provide an innovative, automated insulin delivery (AID) system designed to simplify insulin therapy and improve glycemic control for Canadians living with diabetes.   "The approval of the mylife YpsoPump and CamAPS FX marks an important milestone as we bring these advanced technologies to the Canadian market," said Sébastien Delarive, Chief Business Officer of Ypsomed Diabetes Care. "Although Ypsomed is relatively new in Canada, our established leadership in diabetes care throughout Europe provides a solid foundation for delivering innovative solutions to Canadians living with type 1 diabetes."   "We are excited to see both mylife YpsoPump and CamAPS FX approved," said Karina Schneider, General Manager at Ypsomed Canada. "This step brings us closer to offering an integrated solution that will help simplify diabetes management for Canadian patients, empowering them to take more control of their health." https://finance.yahoo.com/news/ypsomed-camdiab-receive-health-canada-205500840.html XX The FDA updates the labels for all GLP-1 receptor agonists with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). the Medication Guide section of the label also has new additions. Patients are counseled to tell their healthcare provider if they are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). They are alerted that the GLP-1 RAs they are taking may cause serious side effects, including food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sedation. Patients are advised to tell all their healthcare providers that they are taking a GLP-1 RA before they are scheduled to have surgery or other procedures. https://www.medscape.com/viewarticle/fda-updates-glp-1-label-pulmonary-aspiration-warning-2024a1000k84?form=fpf XX Following an impressive data drop this summer highlighting the potential for Eli Lilly's tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drugmaker is laying out full results from its longest completed study of the dual GIP/GLP-1 receptor agonist to date. In the three-year SURMOUNT-1 trial, tirzepatide curbed the risk of disease progression to Type 2 diabetes by 94% versus placebo in adult prediabetes patients who were obese or overweight, Lilly said in a release Wednesday. The number represents a pooled result from three tirzepatide doses (5 mg, 10 mg and 15 mg) studied in the trial.   Putting those results into perspective, one new case of diabetes could be prevented for every nine patients treated with tirzepatide, which is marketed in the U.S. as Mounjaro for Type 2 diabetes and as Zepbound for obesity, Lilly said. https://www.fiercepharma.com/pharma/lilly-unwraps-detailed-data-showing-tirzepatide-kept-nearly-99-pre-diabetic-patients XX Edgparke commeical? XX https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions XX XX And finally, many of you have likely already heard but we had some incredibly tragic news in the diabetes community, especially for the Breakthrough T1D ride community. I'm going to read from the Breakthrough T1D website: The leadership, staff, and volunteers of Breakthrough T1D mourn the tragic, sudden loss of five T1D Champions on Friday, Nov. 1, 2024.  Jeff and Michelle Bauer, Josh and Tammy Stahl and Barry Sievers were all killed in a singe car crash. The group included two married couples and one single individual—all very close friends and veteran Breakthrough T1D Ride participants. Of this incredibly impactful group, I knew Michelle Bauer personally, I met her as Michelle Alswager – you may know her as Jesse's mom. Her son, Jesse died from complications of type 1 in 2010. And that year, mile 23 on the JDRF ride was created as a mile of silence in memory of Jesse.  Now all riders are asked to ride in silence for that mile not only in memory of Jesse, but all those lost to type 1 diabetes. Michelle wrote her book, Jesse Was Here and created a program that's part of Beyond Type 1 to this day, all to help other families going through grief. She called me a few years ago when she was thinking of writing her book and I'm so grateful for our conversations and that our conversations may have helped her get it out there into a world where it's so needed. But we need Michelle here to talk about grief. More about talking to Michelle about the book).   Please, write the book, ride the bike, do the ironman, follow your heart and your dreams.  All of these incredible people gone too soon. https://www.breakthrought1d.org/news-and-updates/breakthrough-t1d-mourns-tragic-sudden-loss-of-five-ride-champions/   Thanks for joining me..

Hope and Progress in Type 1 Diabetes Management In honor of World Diabetes Day earlier this week, this podcast episode celebrates the strength of our T1D Moonshot Community and explores innovative solutions for better insulin delivery management. This episode features inspiring conversations with: Ole Kjerkegaard Nielsen, PhD, CEO & Co-founder of GO-Pen: Making insulin pens more affordable and accessible Bill Ervin, CEO & Founder of Bulsai: Revolutionizing injection techniques for optimized results Discover how these groundbreaking ventures are: Empowering patients with better tools and technology Addressing key frustrations in current diabetes management Plus, learn about StartUp Health's Health Moonshot Communities, like the T1D Moonshot Community, and how they connect founders tackling the biggest health challenges, such as Type 1 diabetes. This episode is a must-listen for anyone impacted by Type 1 diabetes, healthcare professionals, and innovators passionate about improving patient lives. Listen now and join the movement for a brighter future! Are you ready to tell your story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of StartUp Health's PRO Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

The number of adults living with diabetes worldwide has exceeded 800 million, more than quadrupling since 1990. This is according to new data published in the journal The Lancet on World Diabetes Day.Also on the programme: Police in Brazil say an attack on the Supreme Court was a terrorist incident; and there is growing anger over Donald Trump's choices for some of the most powerful positions in the next US government, particularly his choice of Attorney General.(Photo: A person using a set of weighing scales. Credit: PA)

PJ talks to Paloma about discovering she has Diabetes and to Charlotte Pearson of Diabetes Ireland as we mark World Diabetes Day. Hosted on Acast. See acast.com/privacy for more information.

The realities of living with type one as a child in the UAE.See omnystudio.com/listener for privacy information.

World Diabetes Month, observed every November, is a global campaign aimed at raising awareness about diabetes and its impact on individuals and communities worldwide. Organized by the International Diabetes Federation (IDF), this month-long initiative seeks to educate the public on the prevention, management, and treatment of diabetes, while also advocating for better healthcare policies and support systems for those living with the condition. Today is also recognized as World Diabetes Day, so we thought it fitting to engage endocrinologist, Dr. Ariane Davis-Simmons and director of weight loss solutions here at Doctors Hospital, Dr. Janette Martin. Listen in as we have a riveting conversation on the disease, statistics in The Bahamas, the need for support and steps for management. Share & Subscribe #diabetesawareness #worlddiabetesday

Today is World Diabetes Day. Diabetes and well-being is the theme for World Diabetes Day. This evening, an event for those with Type 1 diabetes will be held in Ennis from 7:30pm to 9:30pm. To discuss her experience and more, Alan Morrissey was joined in-studio by Co-founder of Thriveabetes, Gráinne Flynn who is also a volunteer with Diabetes Ireland. Photo (c): Clare FM

World Diabetes Day: Raising awareness in the Eastern Cape with health screenings by Radio Islam

On Thursday morning, East Coast Breakfast marked World Diabetes Day with a special guest, Dr. Steph Osborn, an expert in hyperbaric oxygen therapy. Dr. Osborn joined us to answer listener questions about diabetes, including if it's curable, and what symptoms to look out for. She also shared insights into how hyperbaric oxygen therapy can support diabetes management. Listen to the full conversation on the podcast at ecr.co.za, just select East Coast Breakfast! Webpage

Diabetes is a serious condition that affects millions worldwide and, in Nigeria, it is becoming increasingly prevalent. For individuals whose parents or close family members have diabetes, the risk of developing the disease can be significantly higher. But is there hope for prevention? Can the cycle be broken?Join us on this episode of Nigeria Daily as we try to find answers to these questions.

In honor of World Diabetes Day on November 14, we are sharing a bit of knowledge about a silent killer that affects more than 38 million Americans. What is it, what causes it, and what can we do to treat it? 

50% of millennials think they're headed for one - but 81% can't afford it!See omnystudio.com/listener for privacy information.

In her mid-20s and thriving in a fast-paced communications job, Mila Clarke began experiencing symptoms reminiscent of those her mom had managed with diabetes for years. However, as time went on, it became clear that this was different. Little did she know, her life was about to take a significant turn, leading her on an unexpected journey with a chronic illness she never saw coming.Support the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Tami Harker and Keri Bloom joined Samantha Rux on Wake Up Tri-Counties to discuss Diabetes Awareness.  November is Diabetes Awareness Month and November 14th is World Diabetes Day. 

In this episode, we dive deep into the emotional side of diabetes, exploring how well-being plays a vital role in managing type 2 diabetes and prediabetes. With 36% of people experiencing diabetes distress and 63% living in fear of complications, it's clear that the mental and emotional toll of diabetes is just as significant as the physical aspects. You'll learn practical strategies to manage these challenges, improve your emotional health, and take small steps to prioritize your overall well-being.We also discuss powerful tools like future pacing—a mindset technique that helps you visualize your healthier, future self and use that vision to stay motivated and take positive action today. Whether you're newly diagnosed or have been managing diabetes for years, this episode will offer you support, encouragement, and real-world steps to help you thrive, not just survive, with diabetes.CHAPTERS1:14 Share diabetes awareness with others2:00 World Diabetes Day 2024 theme4:02 Dimensions of well-being6:06 Understanding diabetes distress8:08 Overcoming fear of complications11:32 Building a thrive mindset13:07 Future pacing to create better health and well-being18:29 Take care of your well-being each dayFor show notes and resources, please visit: https://Type2DiabetesTalk.comTo share your questions and suggestions, leave us a voice message or email at: https://Type2DiabetesTalk.com/messageExplore our proven programs and services, visit: https://Type2DiabetesTalk.com/programsSubscribe to our free weekly newsletter for podcast updates, valuable nutrition tips and more: https://Type2DiabetesTalk.com/subscribe

In today's episode, in honor of World Diabetes Day, we're diving deep into diabetes. Did you know that one in two people in the United States have either prediabetes or diabetes? This means that even if you don't have diabetes, someone you love probably does. Today, we break down what diabetes is, the differences between type 1 and type 2, whether prediabetes and diabetes are reversible, and most importantly, why having diabetes should never be a source of shame. We're joined by the two lovely ladies from the Diabetes Digital Podcast, and if you have more questions, you can find additional information on their website.For weekly episodes, come join the Foodie Fam!https://www.patreon.com/FWNTTTo get a summary of everything we talked about today, sign up for our email list. Check out our book:https://read.macmillan.com/lp/food-we-need-to-talk/Chat with us on IG!https://www.instagram.com/foodweneedtotalk/?hl=enBe friends with Juna on IG and Tiktok!https://www.instagram.com/theofficialjuna/https://www.tiktok.com/@junagjata

In this special episode, we sit down with Dr. Jackie Kassouf Maalouf, founder of DiaLeb to commemorate World Diabetes Day. DiaLeb is the National Diabetes Organization. It was founded in 2011 as a non-profit organization in Lebanon to promote diabetes care and prevention and help find a cure for this disease.  We explore the impact of diabetes on communities in Lebanon before and after the economic crisis and we discuss the importance of lifestyle modification as a preventative measure for type 2 diabetes. We also discuss the multiple projects that DiaLeb has been involved in promoting exercise and nutrition, and helping provide needed medications to people suffering from diabetes in Lebanon.  Tune in for this enlightening conversation which was recorded before the current war in Lebanon, but which provides hope for a bright future in Lebanon.  This episode is also available on Youtube: https://youtu.be/4hFBDbH0gJk and on all podcast apps.  #Diabetescare #Worlddiabetesday #diabetes #diabetesprevention #lifestyle

This is a bitesize episode of 'The insuleoin Podcast - Redefining Diabetes'. Each week we'll take a look back into the archive of episodes and get you to think and reflective once more about some of the things we've learned over the past few years. In this week's BITESIZE:Raising your own awareness for your own diabetes. Identify things that give you energy and dilute your energy. Doing the small things consistently. To hear the full episode check out episode #141: Bursting Through a Trampoline & Breaking Both Legs, World Diabetes Day! Hosted on Acast. See acast.com/privacy for more information.

"The doctor said: 'You need to put your phone down because we have to get this drip into your arm, otherwise you're going to die.' And that was my introduction to type 1 diabetes."Today's guest is Harriet Minter - published author, journalist, coach and gender equality specialist.Harriet has worked and written for among others, The Guardian, The Times and the Telegraph. She's a columnist for Psychologies magazine, and created the wildly successful Badass Women's Hour podcast and live radio show, which she was very much in the throes of when she received that terrfying type 1 diabetes diagnosis on World Diabetes Day 2020, at the age of 38.That horrifying diagnosis was in the midst of the pandemic, and it has since altered Harriet's relationships with her work, her loved ones, and ultimately herself.Wise, sharp and insightful, this is an incredibly thought-provoking chat, covering the vulnerability that diabetes forces you to face, the conflict of becoming both more independent and more willing to ask for help, accepting her body's limits, stigma around body size and diabetes, diabetes in the workplace and my favourite new phrase - SOFT POWER. Oh, and don't speak to Harriet about glucose monitoring as a health trend...This was such a treat to record, I hope you enjoy it! Be sure to check out Harriet's writing on her Substack too - aptly titled We Can't Do It Alone. CONNECT WITH HARRIETSubscribe to Harriet's Substack.Follow Harriet on Instagram.JOIN THE TYPE 1 ON 1 INSTAGRAM COMMUNITYWe've got an Instagram account! Come and say hi @studiotype1on1 SPONSOR MESSAGEThanks to my episode sponsors Insulet, the founders of Pod Therapy - only found with Omnipod. Pod Therapy uses a tubeless, wearable and waterproof Pod that continuously delivers insulin for up to three days. Controlled wirelessly by its handheld companion, it allows you to personalise your insulin doses according to your own daily needs - no multiple daily injections and no tubes. Head to https://www.omnipod.com/ to find out more.

In this episode of Diabetics Doing Things, sponsored by Medtronic, Rob is joined by Monique La Bomme, in an episode recorded live on World Diabetes Day at the Medtronic Diabetes headquarters in California. Monique shares her experience of living with type 1 diabetes and discusses her journey with diabetes alert dogs and diabetes management technology. The conversation also delves into the importance of representation and advocacy in the diabetes community. Topics discussed: 1. Monique's diagnosis story and early days with diabetes 2. Diabetes management, technology, and the use of diabetes alert dogs 3. Representation and advocacy in the diabetes community 4. The impact of diabetic alert dogs on people's lives 5. Balancing diabetes management and social life as an actor and model Here are key takeaways and lessons: - Monique shares her diagnosis story, highlighting the importance of early detection and the role of a lung specialist in her diagnosis. - Her positive experience with diabetes management at a children's hospital and the supportive diabetes community during her early days with diabetes. - The significance of diabetes alert dogs in detecting glucose changes and preventing severe hypoglycemia incidents. - The importance of representation and advocacy in the diabetes community, especially in showcasing diverse experiences and stories. - The impact of diabetic alert dogs on raising awareness and inspiring others to consider using service dogs for diabetes management. References: - Instagram handle: Monique La Bomme - [@moniquenicolee] (https://www.instagram.com/moniquenicolee/) - Medtronic - [Medtronic Diabetes](https://www.medtronicdiabetes.com/) - World Diabetes Day - [International Diabetes Federation](https://www.idf.org/our-activities/world-diabetes-day.html) 00:00  Live from Medtronic HQ: A Type 1 Diabetes Journey on World Diabetes Day 05:09  Navigating Type 1 Diabetes: Community Support and Advanced Technology 09:40  How a Diabetic Alert Dog Changed My Life: Monique's Story 19:33  Breaking Barriers: Advocating for Diversity and Inclusivity in the Diabetes Community

Meet Simone Carniglia, Six-Star finisher, and Guinness World Record holder as the fastest runner with Type One diabetes—with an amazing average time of 2:42:30 per race! Simone started his running journey to lose weight and was inspired by Stefano Baldini, the great Italian marathoner who won the gold medal at the 2004 Athens Olympics. Running these incredibly fast times is impressive, but for a diabetic, it is significantly more challenging. A diabetic marathoner has to continuously control blood sugar levels in order to be safe, not faint, and perform at their best. They're more subject to cramping and dehydration during physical activity, especially when glucose levels aren't managed properly. Simone has only been running for five years and is just getting started. He hopes his journey will inspire many other diabetic athletes to not give up on their dreams and never give up. Simone's story proves that with the right training, nutrition, therapy, strategy, and use of the latest technologies—such as Abbott Global and Freestyle Libre 3—diabetic runners can achieve amazing results that weren't imaginable just a few short years ago Simone is grateful for the Abbott Global profile they featured on him for World Diabetes Day and is excited to get started on a second round of World Marathon Majors. I'm rooting for Simone to keep inspiring and look forward to seeing him out there in 2024! If you enjoy the episode, it would mean the world to me if you would rate the podcast or write a review and share feedback wherever you get your podcast groove on. Connect With Simone: Instagram: https://www.instagram.com/simone.carniglia All Other Links: https://linktr.ee/6majorswitht1d Connect With Ron: Personal Instagram: https://www.instagram.com/ronrunsnyc Podcast Instagram: https://www.instagram.com/runchats_with_ronrunsnyc Facebook: https://fb.me/runchats Website: https://ronrunsnyc.com ---- Produced by: David Margittai | In Post Media Website: https://www.inpostmedia.com Email: david@inpostmedia.com Social: https://www.instagram.com/_margittai © 2023 Ron Romano

Context of White Supremacy hosts the weekly Compensatory Call-In. We encourage non-white listeners to dial in with their codified concepts, new terms, observations, research findings, workplace problems or triumphs, and/or suggestions on how best to Replace White Supremacy With Justice ASAP. This weekly broadcast examines current events from across the globe to learn what's happening in all areas of people activity. We cultivate Counter-Racist Media Literacy by scrutinizing journalists' word choices and using logic to deconstruct what is reported as "news." We'll use these sessions to hone our use of terms as tools to reveal truth, neutralize Racists/White people. #ANTIBLACKNESS The St. Louis International Film Festival had a wealth of documentaries at this year's event. One of them was, We Are Distance Runners: The Marathon Hat Trick - which details black female and male marathon runners who travel the planet to compete against White people in foot races. Tony Reed and Lisa Davis each said a part of the influence for their running is that they both had attempted black family members suffer greatly from diabetes. Unbeknownst to Gus, earlier this week, many people recognized World Diabetes Day. Dr. Frances Cress Welsing told us that black people do not qualify for mental health. Given the toxic plantation Racists force black people to uphold, it's no surprise that black people around the world are burdened with poor diets and the accompanying maladies like diabetes. #NoProcessedWhiteSugar #TheCOWS14Years INVEST in The COWS – http://paypal.me/TheCOWS Cash App: https://cash.app/$TheCOWS CALL IN NUMBER: 605.313.5164 CODE: 564943#

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Novo Nordisk will discontinue Levemir by the end of 2024, Tandem begins limited launch of software updates that will include Dexcom's G7, Beta Bionics iLet pump will be covered until some pharmacy plans, and lots more! Links and transcript below Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX This week was World Diabetes Day so there is a LOT going on.. Our top story is XX Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The Danish drugmaker said supply disruptions would start in mid-January, followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024. Novo has another long-acting insulin, Tresiba, on the market and says quote - "global manufacturing constraints, significant formulary losses impacting patient access effective in January 2024, and the availability of alternative options in the U.S. market" are key factors in the decision. The announcement comes eight months after Novo said it would cut U.S. list prices for several of its insulin products next year, including a 65% reduction in the list price of Levemir. Novo, which overtook LVMH (LVMH.PA) as Europe's most valuable listed company this year, posted record operating profit for the third quarter, with sales of its obesity drug Wegovy reaching $1.36 billion, up 28% from the previous quarter. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-discontinue-levemir-insulin-us-market-2023-11-08/ XX Big news from Tandem Diabetes this week – first, their Control IQ algorithm gets FDA approval for children as young as two years old. the technology's original 2019 clearance limited its use to those aged 6 and older. And.. they are officially rolling out the software update that will allow users to connect to either the Dexcom G6 or G7 CGM. If you're in the limited launch you got an email this week telling you the next steps – wider release is expected gradually in the first part of 2024. Integration with Abbot's FreeStyle Libre is expected very soon as well – which would mean Tandem's tslim x2 and Mobi pumps would be compatible with three CGMs. Full disclosure: there wasn't a media release that I received on this, but my son is in the limited launch group so we got the email.   https://www.fiercebiotech.com/medtech/tandem-diabetes-care-cruises-fda-ok-toddler-use-automated-insulin-delivery-algorithm XX Beta Bionics iLet pump and its supplies are now covered as part of some pharmacy benefits - Express Scripts added it to its national formulary list. Historically, insulin pumps fall under the durable medical equipment (DME) insurance benefit. Usually pharmacy benefits are more flexible with fewer up front costs. The system uses an adaptive, closed-loop algorithm that initializes with the user's body weight and requires no additional insulin dosing parameters. The algorithm removes the need to manually adjust insulin pump therapy settings and variables. iLet simplifies mealtime use by replacing conventional carb counting with its meal announcement feature. This enables users to estimate the amount of carbs in their meal, categorized as “small,” “medium” or “large.” Over time, the algorithm learns to respond to users' individual insulin needs. https://www.drugdeliverybusiness.com/beta-bionics-pharmacy-benefit-bionic-pancreas/ XX The UK has launched a pioneering study to explore the development of type 1 diabetes in adults which aims to screen 20,000 individuals. Research will enable earlier and safer diagnosis of type 1 diabetes through blood tests. This makes the UK the first country to implement general population screening for type 1 diabetes in both children and adults. The Type 1 Diabetes Risk in Adults (T1DRA) study, launched on World Diabetes Day, seeks to enroll 20,000 adults aged 18 to 70. Supported by The Leona M. and Harry B. Helmsley Charitable Trust and building on the Diabetes UK-funded Bart's Oxford Family study (BOX), T1DRA aims to unravel the mysteries of adult-onset type 1 diabetes. https://www.diabetes.co.uk/news/2023/nov/groundbreaking-study-to-screen-20000-adults-for-type-1-diabetes.html XX The National Institute for Health and Care Excellence (NICE), England's cost-effectiveness watchdog, has finalized a draft guidance regarding hybrid closed-loop systems, concluding that the technology should be made broadly affordable and accessible to help people with Type 1 diabetes better manage the condition. In this month's final draft guidance (PDF), NICE recommended that hybrid closed-loop technology be offered to all people with Type 1 diabetes who are having trouble controlling the condition using their existing devices.   NICE said that it has already devised a five-year rollout plan with the NHS to bring the technology to people with Type 1 diabetes. Hybrid closed-loop systems will be offered first to children, young people, existing insulin pump users and women who are pregnant or planning to become pregnant, after which they'll be issued to adults who have an average HbA1c reading of at least 7.5%. https://www.fiercebiotech.com/medtech/nice-recommends-hybrid-closed-loop-systems-type-1-diabetes-prompting-praise-medtronic XX     Commercial XX Kyle Banks was diagnosed with type 1 diabetes on November 1, 2015 while performing with the traveling production of Disney's The Lion King.  Performing nightly for sold out audiences across the country was a dream come true, but after experiencing symptoms of the onset of type 1 diabetes, the dream temporarily turned into a nightmare. The symptoms he experienced were  typical for the onset of this chronic illness. but with limited knowledge of type 1 diabetes, he had no idea what was occurring or the drastic life change that would soon follow.  In 2020, he founded Kyler Cares in partnership with Children's Hospital New Orleans and has since connected with families from across the country that are living with this disease.  Kyler Cares seeks to improve health outcomes for people of color living with diabetes and ensuring families can access the resources and technology available for better management is the route the organization is taking to achieve that goal. At Kyler Cares we're working to improve health outcomes for people of color living with diabetes by improving access to diabetes technology, creating connections to education and resources, and fostering community as an added system of support on our journeys. Kyler Bear & Friends' T1 Diaries is an eight-part animated series for kids, dedicated to storytelling about life with Type 1 Diabetes. Our series is more than just an educational tool; it's a reflection of real-life stories and an avenue to strengthen community ties. It's a vehicle for us to inspire young people to begin laying a foundation of knowledge and self-confidence with management of T1D that will resonate throughout their lives until a cure for the disease is discovered.   By supporting this series with a donation, you will be contributing to a project that not only educates and informs but also offers comfort and a sense of belonging to kids navigating life with T1D. ‘Kyler Bear's T1 Diaries' isn't just a series; it's a beacon of hope, a source of information, and a testament to the strength found in our amazing T1D community. Join us in bringing these stories to life XX Married At First Sight UK ends this week, but one bride says viewers haven't seen her whole story.   Fans will find out if Tasha Jay, 25, decides to stay with partner Paul Liba on the Channel 4 show.   But Tasha, who has type 1 diabetes, has spoken out about how footage about her condition didn't make the final cut.   While she's "really sad" that it was left out, Tasha's pleased that people are now realising why she behaved in a certain way on the show at times.     Married at First Sight - or MAFS - is a social experiment where experts match complete strangers who try to live as a couple.   Tasha says her wedding day with Paul on the show was a "really beautiful moment" that included her telling Paul about her diabetes and his reaction.   "I got filmed taking my insulin and checking my blood sugar," she tells BBC Newsbeat.. Tasha was diagnosed at aged two and half and says people have asked why that part of her was hidden in the show.   "And I'm like I didn't hide it," she says.   "For whatever reason they haven't shown it, which really upsets me because diabetes is a part of my story."   Tasha believes that, if people had known about her diabetes, it would have changed their perception of certain moments in the show. https://www.bbc.com/news/newsbeat-67368445

Amanda kicks things off with health awareness on World Diabetes Day, reminding us to be mindful of what we consume, even for our furry friends. National Seat Belt Day urges us to buckle up for a fantastic show ahead. Blackurate News delves into Lloyd's of London's apology for its role in slavery, sparking a discussion on reparations. The Voting and Venting segment features listener calls on various voting-related topics. SAG-AFTRA's resolution with Hollywood studios after a 100-day strike is explored, with Amanda weighing in on key aspects. A Color Purple quiz for team members adds a fun twist, followed by a thought-provoking segment on Whoopi Goldberg's views on millennials and Gen Z-ers' work ethic. The episode wraps with insights on recent headlines, a Color Purple quiz, and Amanda's witty take on politicians.   Listen, Laugh, and Learn with The Amanda Seales Show   FOLLOW ALONG AS WE COVER:   (4:58) - Whoopi Goldberg is receiving backlash after suggesting millennials and Gen Z-ers have poor work ethic. A recent episode on “The View” featured the hosts discussing the current economic climate, including housing, finances, and being parents. Let's hear Whoopi's comments.   (9:50) - It's time for our new segment– Voting and Venting! This is your opportunity (and mine) to vent about anything related to voting– contemplating who should get your vote? Vexed about certain laws being voted on in your city? We wanna hear about it! It's time to vent. Let's go to the phone lines.   (14:17) - 60 Second Headlines   Beyoncé dropped a brand new trailer for her upcoming tour film. The movie takes us behind the scenes of her Renaissance world tour. NY Attorney General Letitia James has announced that Uber and Lyft will start laying plans to implement a minimum wage and paid sick leave for drivers in the New York area. Dr. Jill Stein has announced a surprise presidential bid, seeking the Green Party's 2024 nomination! Atlanta's nightlife may get a boost as the city proposes to extend “last call” from 2:30 am until 4 am under the Atlanta Hospitality Act. A Judge has granted prosecutors the right to present a collective of Young Thug's rap lyrics in the trial against him and his YSL associates amid their controversial RICO case.   (17:06) – We'll go to the phone lines.   (21:29) - Coming up this hour in Blackurate News:   The UK insurance market, Lloyd's of London, says they are deeply sorry for their role in the slave trade. That's it? Sorry?! Also, after over 100 days, the actors' strike is over. We'll highlight some of the terms of the deal. Plus, the Big Up/Let Down… The Big Up goes to a flight attendant, and the Let Down goes to some teeth… I'll explain in a minute!   (26:00) - Lloyd's of London, the giant U.K. insurance and reinsurance market founded in 1688, has apologized for its historic link to slavery. “We are deeply sorry for the Lloyd's market's participation in the transatlantic slave trade. It is part of our shared history that caused enormous suffering and continues to have a negative impact on Black and ethnically diverse communities today.” Lloyd's announced steps to make amends, including investing the equivalent of $48.8 million and introducing comprehensive initiatives to tackle inequality toward Black and ethnically diverse individuals.   (30:08) - After over 100 days of picketing, SAG-AFTRA struck a new tentative deal with Hollywood's major studios -- effectively ending the actors' strike. The 118-day strike was one of the longest labor outages in Hollywood history. Among the studio heads who came to the negotiating table during the SAG strike were Bob Iger of Disney, Donna Langley of NBCUniversal Studio Group, Ted Sarandos of Netflix, and David Zaslav of Warner Bros. Discovery.   (35:47) – The Big Up/Let Down:   Big Up - In a viral post, a Grammy-nominated gospel singer named Bobbi Storm went head-to-head with a flight attendant after she wanted to serenade the whole flight with a song, and he shut her all the way down!!!! Big Up - To this flight attendant for not taking her to Jesus for all this racket. This was completely out of order! People are trying to sleep! What if you woke somebody's baby up?! You can't just hijack the plane with your voice. Even if it is pretty. She was trying to give herself the glory, not Jesus! Also, big up to the folks with noise-canceling headphones who heard none of this! Let Down: Rapper and toxic partner in crime to Blueface, Chrisean Rock, joined Tamar Braxton onstage at a concert this past weekend but she didn't leave before allegedly assaulting, James Wright, Tamar's stage hand (famous for his Patti Pies review). She supposedly caused a severe nosebleed and chipped his tooth. The letdown goes to…. these weak ass 2023 teeth!   (41:09) – We'll go to the phone lines. 1-855-262-6328.   (43:20) - Coming up: We're gonna give Rita and TJ, who have never seen the original Color Purple movie, a Color Purple Quiz!   (46:15) – We'll play the Color Purple Quiz.   (52:44) – The actors' strike is over! Amanda gives more insight.   (57:25) – We'll go back to the phone lines.   (1:00:46) - It's time to listen, laugh, and learn… with the Word of the Day. The Word of the Day is: Bugbear - Noun A source of dread or irritation; something that causes problems or annoys people.   (1:04:08) – Politicians say the smartest things.   (1:08:54) – Thanks for listening to The Amanda Seales Show.   FOLLOW THE SHOW ON ALL SOCIALS: @Sealessaidit @Amandaseales @Jeremiahlikethebible If You Have A Comment Leave Amanda A Message At 1 855-Amanda-8 That's 1-855-262-6328  See omnystudio.com/listener for privacy information.

November 14th is World Diabetes Day. My daughter lives with Type 1 Diabetes and this day is very near and dear to my heart. In honor of Dr. Banting, who discovered insulin in 1921, we are talking about sharing your gifts with the world. It's time to stop sitting around feeling scared to try. You never know how you could change someone else's life! Get the show notesGo behind the scenes with me on IG @IrresistibleIcingHead over to the free Irresistible You Podcast Discussion Group to continue the conversation about this episode and more!Support the podcast by leaving a free rating & review on Apple Podcasts or buy me a coffee.Support the show

As we observe World Diabetes Day, we delve into the complex landscape of diabetes in China and beyond. From skyrocketing cases to the influence of lifestyle, we dissect the sweet dilemma that millions face daily. Join us as we examine the multifaceted factors that contribute to the rise of diabetes, question how the world can collectively combat the silent epidemic of diabetes. On the show: Niu Honglin, Xingyu & Brandon Yates